- Home
- Publications
- Publication Search
- Publication Details
Title
Medical treatment of prolactinomas
Authors
Keywords
-
Journal
Nature Reviews Endocrinology
Volume 7, Issue 5, Pages 267-278
Publisher
Springer Nature
Online
2011-03-22
DOI
10.1038/nrendo.2011.37
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: A metaanalysis from clinical studies
- (2014) F. Bogazzi et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Prevalence of Valvular Heart Disease in a Cohort of Patients Taking Cabergoline for Management of Hyperprolactinemia
- (2013) Jessica Devin et al. Endocrine Practice
- Dopamine agonists and valvular heart disease
- (2011) Dianne Cheung et al. Current Opinion in Endocrinology Diabetes and Obesity
- ORIGINAL ARTICLE: Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia
- (2010) Tricia Tan et al. CLINICAL ENDOCRINOLOGY
- Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline
- (2010) M Lafeber et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Potential Cardiac Valve Effects of Dopamine Agonists in Hyperprolactinemia
- (2010) Elena Valassi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience
- (2010) Gérald Raverot et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Atypical pituitary adenomas: incidence, clinical characteristics, and implications
- (2010) Gabriel Zada et al. JOURNAL OF NEUROSURGERY
- Management of prolactinomas in Brazil: an electronic survey
- (2010) Lucio Vilar et al. Pituitary
- The prolactinoma
- (2009) Annamaria Colao BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Valvular heart disease and the use of cabergoline for the treatment of prolactinoma
- (2009) Neil Herring et al. CLINICAL ENDOCRINOLOGY
- Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study
- (2009) Lisa B. Nachtigall et al. CLINICAL ENDOCRINOLOGY
- Factors determining the remission of microprolactinomas after dopamine agonist withdrawal
- (2009) M. S. B. Huda et al. CLINICAL ENDOCRINOLOGY
- Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients
- (2009) Etienne Delgrange et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Recurrence of Hyperprolactinemia after Withdrawal of Long-Term Cabergoline Therapy
- (2009) J. Kharlip et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Evolution of an Aggressive Prolactinoma into a Growth Hormone Secreting Pituitary Tumor Coincident with GNAS Gene Mutation
- (2009) Andrea G. Lania et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis
- (2009) Olaf M. Dekkers et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review
- (2009) Malcolm Steiger et al. JOURNAL OF NEURAL TRANSMISSION
- USE OF TEMOZOLOMIDE IN AGGRESSIVE PITUITARY TUMORS
- (2009) Safraz Mohammed et al. NEUROSURGERY
- Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours
- (2008) Ann I. McCormack et al. CLINICAL ENDOCRINOLOGY
- Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required
- (2008) M Kars et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Cabergoline and the risk of valvular lesions in endocrine disease.
- (2008) Patrizio Lancellotti et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease
- (2008) Ammar Wakil et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia
- (2008) F. Bogazzi et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients
- (2008) Masami Ono et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma
- (2008) Marleen Kars et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Increased Prevalence of Tricuspid Regurgitation in Patients with Prolactinomas Chronically Treated with Cabergoline
- (2008) Annamaria Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Bromocriptine use and the risk of valvular heart disease
- (2008) Louis C.S. Tan et al. MOVEMENT DISORDERS
- Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists
- (2008) Frank Andersohn et al. MOVEMENT DISORDERS
- Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas
- (2008) Sophie Vallette et al. Pituitary
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started